JP2022535452A5 - - Google Patents

Info

Publication number
JP2022535452A5
JP2022535452A5 JP2021572559A JP2021572559A JP2022535452A5 JP 2022535452 A5 JP2022535452 A5 JP 2022535452A5 JP 2021572559 A JP2021572559 A JP 2021572559A JP 2021572559 A JP2021572559 A JP 2021572559A JP 2022535452 A5 JP2022535452 A5 JP 2022535452A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021572559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036495 external-priority patent/WO2020247873A1/en
Publication of JP2022535452A publication Critical patent/JP2022535452A/ja
Publication of JP2022535452A5 publication Critical patent/JP2022535452A5/ja
Ceased legal-status Critical Current

Links

JP2021572559A 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用 Ceased JP2022535452A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858932P 2019-06-07 2019-06-07
US62/858,932 2019-06-07
US201962888384P 2019-08-16 2019-08-16
US62/888,384 2019-08-16
PCT/US2020/036495 WO2020247873A1 (en) 2019-06-07 2020-06-05 Antigen-binding protein constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2022535452A JP2022535452A (ja) 2022-08-08
JP2022535452A5 true JP2022535452A5 (enExample) 2023-06-13

Family

ID=71899864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572559A Ceased JP2022535452A (ja) 2019-06-07 2020-06-05 抗原結合タンパク質構築物およびその使用

Country Status (9)

Country Link
US (1) US20220313845A1 (enExample)
EP (1) EP3980129A1 (enExample)
JP (1) JP2022535452A (enExample)
CN (1) CN114746115A (enExample)
AU (1) AU2020289477A1 (enExample)
CA (1) CA3142884A1 (enExample)
IL (1) IL288685A (enExample)
MX (1) MX2021015095A (enExample)
WO (1) WO2020247873A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Ｄｌｌ３抗原結合構築物
CN119486763A (zh) * 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
TW202602935A (zh) * 2024-04-01 2026-01-16 美商米西克治療公司 抗原結合蛋白構築體及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE

Similar Documents

Publication Publication Date Title
Wang et al. Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment
JP6817492B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
Boado et al. Fusion antibody for alzheimer's disease with bidirectional transport across the Blood− Brain barrier and Aβ fibril disaggregation
Kubetzko et al. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5
JP2022543771A5 (enExample)
Wu et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
WO2020253568A1 (zh) 抗cd73抗体及其应用
CN106573983B (zh) 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段
CN115960230A (zh) 靶向分子的抗原结合构建体
KR20190031299A (ko) 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
US20200255536A1 (en) Target for b-cell disorders
JP2022553922A5 (enExample)
JP2022534808A5 (enExample)
RU2013134983A (ru) Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области
JP2023544143A5 (enExample)
JP2021529776A5 (enExample)
JP2025181917A5 (enExample)
CZ20013270A3 (cs) Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob
Cini et al. SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
JP2023103439A (ja) 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤
JP2025518493A5 (enExample)
AR129303A1 (es) Anticuerpos monoclonales dirigidos contra la proteína de muerte celular programada 1 y su uso medicinal
JP2022551844A5 (enExample)
EP4467573A1 (en) Bispecific binding molecule